Stockscreener 앱 받기
23.29
1.34%
0.25
전일 마감가:
$23.04
열려 있는:
$23.04
하루 거래량:
1.11M
Relative Volume:
0.55
시가총액:
$4.43B
수익:
$219.12M
순이익/손실:
$-453.82M
주가수익비율:
-5.9718
EPS:
-3.9
순현금흐름:
$-419.68M
1주 성능:
-3.16%
1개월 성능:
-7.20%
6개월 성능:
-20.26%
1년 성능:
-17.53%
1일 변동 폭
$22.82
$23.63
1주일 범위
$21.72
$24.30
52주 변동 폭
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BBIO | 23.30 | 4.43B | 219.12M | -453.82M | -419.68M | -3.90 |
| VRTX | 450.01 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.02 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 594.70 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.85 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.66 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
When (BBIO) Moves Investors should Listen - Stock Traders Daily
BBIO (BridgeBio Pharma) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Insider Sell Alert: Brian Stephenson Sells Shares of BridgeBio P - GuruFocus.com
BridgeBio Pharma CEO Neil Kumar sells $613,825 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma CEO Neil Kumar sells $613,825 in stock - Investing.com
BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136 - Investing.com
BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136 By Investing.com - Investing.com UK
Bridge Bio Study Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes in ATTR-CM - DocWire News
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Yahoo Finance
399,781 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by First Turn Management LLC - MarketBeat
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be - Simply Wall St
Royce & Associates LP Invests $3.11 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - BioSpace
Open-Label Extension Data Confirms Sustained Benefit of - GlobeNewswire
BridgeBio's Acoramidis Shows 36% Mortality Reduction in ATTR-CM Trial Extension | BBIO Stock News - StockTitan
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL - The Bakersfield Californian
BridgeBio Pharma Announces Publication in the New England - GlobeNewswire
BBIO FY2024 EPS Estimate Reduced by Cantor Fitzgerald - MarketBeat
Shareholders in BridgeBio Pharma (NASDAQ:BBIO) have lost 44%, as stock drops 12% this past week - Simply Wall St
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $47.57 Average Price Target from Brokerages - MarketBeat
Scotiabank Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $45.00 - MarketBeat
Leerink Partnrs Expects Weaker Earnings for BridgeBio Pharma - MarketBeat
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst — A Buy, With Caveats (BBIO) - Seeking Alpha
Leerink Partnrs Has Negative Outlook of BBIO FY2028 Earnings - MarketBeat
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BridgeBio Pharma Reports Quarterly Loss Amid Restructuring - TipRanks
BridgeBio Pharma Inc (BBIO) Quarterly 10-Q Report - Quartzy
No-Moat BridgeBio's Valuation Driven by Pending Approval of Acoramidis; Positive Long-Term Outlook - Morningstar
BridgeBio Pharma Inc Reports Q3 2024 Revenue of $2.7 Million, Mi - GuruFocus.com
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates - MSN
BridgeBio Pharma earnings beat by $0.13, revenue topped estimates - Investing.com UK
BridgeBio Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Achondroplasia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic - Barchart
Achondroplasia Market to Show Remarkable Growth Trends from - openPR
BridgeBio Pharma: Q3 Earnings Snapshot - San Antonio Express-News
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update - The Manila Times
BridgeBio's Acoramidis Nears FDA Approval; $500M Milestone Payment Awaits | BBIO Stock News - StockTitan
WCM Investment Management LLC Purchases 86,987 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Trend Tracker for (BBIO) - Stock Traders Daily
BridgeBio Announces Publication of Case Study Exploring - GlobeNewswire
BridgeBio Dives on Revealing Case Study - Baystreet.ca
BridgeBio's Portfolio Theory Innovation Reshapes Drug Development Strategy | BBIO Stock News - StockTitan
Achondroplasia Market Forecasted to Surge in Coming Years, - openPR
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Increased by Emerald Advisers LLC - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 8.3%Still a Buy? - MarketBeat
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
(BBIO) Proactive Strategies - Stock Traders Daily
Seven PDUFA dates on FDA’s November calendar - BioCentury
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Secretary, Treasurer & CFO |
Nov 19 '24 |
Sale |
22.41 |
4,156 |
93,137 |
93,758 |
1.80%
0.42%
자본화:
|
볼륨(24시간):